Ignite Creation Date:
2025-12-24 @ 10:46 PM
Ignite Modification Date:
2026-02-19 @ 5:13 PM
Study NCT ID:
NCT03670069
Status:
TERMINATED
Last Update Posted:
2024-05-08
First Post:
2018-09-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Sponsor:
Fred Hutchinson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Leiomyosarcoma | View |
| None | Metastatic Synovial Sarcoma | View |
| None | Metastatic Undifferentiated Pleomorphic Sarcoma | View |
| None | Advanced Myxoid Liposarcoma | View |
| None | Advanced Soft Tissue Sarcoma | View |
| None | Metastatic Myxoid Liposarcoma | View |
| None | Metastatic Round Cell Liposarcoma | View |
| None | Metastatic Soft Tissue Sarcoma | View |
| None | Refractory Leiomyosarcoma | View |
| None | Refractory Myxoid Liposarcoma | View |
| None | Refractory Round Cell Liposarcoma | View |
| None | Refractory Soft Tissue Sarcoma | View |
| None | Refractory Synovial Sarcoma | View |
| None | Refractory Undifferentiated Pleomorphic Sarcoma | View |
| None | Advanced Leiomyosarcoma | View |
| None | Advanced Synovial Sarcoma | View |
| None | Advanced Undifferentiated Pleomorphic Sarcoma | View |
| None | Metastatic Chondrosarcoma | View |
Keywords: